Picture of CEL-SCI logo

CVM CEL-SCI Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m-18.04%
3m-39.3%
6m+18.47%
1yr-36.02%
Volume Change (%)
10d/3m-35.04%
Price vs... (%)
52w High-43.34%
50d MA-23.17%
200d MA-10.41%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-127.13%
Return on Equity-158.25%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Sep 202430th Sep 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of CEL-SCI EPS forecast chart

Profile Summary

CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.

Directors

Last Annual
September 30th, 2023
Last Interim
December 31st, 2023
Incorporated
March 22nd, 1983
Public Since
December 8th, 1983
No. of Shareholders
500
No. of Employees
43
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNYSE MKT
Shares in Issue
53,979,231

CVM Share Price Performance

Upcoming Events for CVM

CEL-SCI Corp Annual Shareholders Meeting

Q2 2024 CEL-SCI Corp Earnings Release

CEL-SCI Corp Annual Shareholders Meeting

Q3 2024 CEL-SCI Corp Earnings Release

Similar to CVM

FAQ